
XAIR Stock Forecast & Price Target
XAIR Analyst Ratings
Bulls say
Beyond Air is undergoing a leadership transition, with Robert Goodman taking over as CEO to drive commercial execution and revenue generation for the LungFit PH system, which has already shown strong traction with increasing revenue and expanding distribution. With the focus now on commercialization and expanding the platform's potential through developments such as in combination with anti-PD-1 treatment, investors can have a positive outlook on the company's growth potential and long-term success.
Bears say
Beyond Air is facing challenges in pushing US utilization and deepening hospital relationships, as well as improving execution internationally. The departures of Todd Lisi and Rob Goodman point to a shift towards a more commercially-oriented strategy. With a low number of sales reported and upcoming catalysts heavily reliant on data from ongoing Phase 1 trials, it may be difficult for the company to gain traction in the market and justify its current valuation.
This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.
XAIR Analyst Forecast & Price Prediction
Start investing in XAIR
Order type
Buy in
Order amount
Est. shares
0 shares